Aptevo Therapeutics (APVO) Share-based Compensation (2015 - 2026)
Aptevo Therapeutics (APVO) posted Share-based Compensation of $57000.0 for Q1 2026, up 1525.0% sequentially from -$4000.0 in Q4 2025, and down 68.33% YoY from $180000.0 in Q1 2025.
Aptevo Therapeutics (APVO) Share-based Compensation (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Share-based Compensation for 12 years, with the latest figure at $57000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 68.33% year-over-year to $57000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $161000.0 (down 85.36% YoY) and the FY2025 annual result came in at $96000.0, down 91.02% from the prior year.
- Share-based Compensation advanced to $57000.0 in Q1 2026 per APVO's latest filing, from -$4000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $915000.0 in Q1 2023 and troughed at -$72000.0 in Q4 2024.
- A 5-year average of $336750.0 and a median of $358000.0 in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 101.12% in 2022, then slumped 120.11% in 2024.
- Over 5 years, Share-based Compensation stood at $358000.0 in 2022, then changed by 0.0% to $358000.0 in 2023, then plunged by 120.11% to -$72000.0 in 2024, then soared by 94.44% to -$4000.0 in 2025, then soared by 1525.0% to $57000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $57000.0, -$4000.0, and $40000.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Aptevo Therapeutics | 3.17 Mn | -6.63 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Dec 31, 2025 | -4,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 180,000.00 |
| Mar 31, 2025 | 180,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Mar 31, 2024 | 719,000.00 |
| Mar 31, 2024 | 719,000.00 |
| Dec 31, 2023 | 358,000.00 |
| Dec 31, 2023 | 358,000.00 |
| Sep 30, 2023 | 455,000.00 |
| Sep 30, 2023 | 455,000.00 |